Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sounds really good for MSPrecise!
Yes, I know.
(MVPL) Mv Portfolios Inc., - 1:100 R/S on Sept. 8, 2014. Was MVP, changed to CLGD and then MVPL
Potential for spin-off in 2015:
LymPro Test
MS Precise
Georgetown Assays
Manf, not until 2018. Yes I agree, MANF will be huge!
Next week Monday the President & CEO, Gerald E. Commissiong, will be presenting at the Noble Financial Capital Markets'
Eleventh Annual Investor Conference being held January 18 - 21, 2015, in
Sandpiper Bay, FL. on Monday, Jan. 19, 2015, 4:30 p.m. Eastern Time
Add it on the board.
Yes, the video is so beautiful! Let me know when you want to add anything else to the board.
Jason Napodano said that Georgetown University is the one that was on CNN / Bloomberg last year and made a big splash. YES! This is a really good news!
I would be crazy to sell my shares. AMBS going to be huge!
I agree! LymPro blood test that can predict with 90 percent accuracy, sounds really good!
Today Conference - http://edge.media-server.com/m/p/79jbs7jf
Wow! That is a lot of shares
DioGenix has preliminary data that suggests our technical approach to MS can be expanded to better understand and improve decision making in other neurological and neurodegenerative diseases, including:
Neuro-sarcoid
Neuromyelitis optica
Paraneoplastic disease
Lupus with neurological involvement
These additional indications are covered by pending patent applications owned by DioGenix. In addition, our approach may be applicable to the diagnosis and monitoring of diseases believed to feature an immune component, for example, amyotrophic lateral sclerosis (ALS), also known as Lou Gerhig’s disease.
These programs will benefit from the access to appropriate patient populations through DioGenix’ extensive neurological clinical network, the company’s molecular profiling platform and the biological connections already made in our MS program.
Wow, AMBS is going to be huge. Added ESS-W and now added DioGenix. What next?
I hope the best for you, good luck!
If they didn't, they might soon. Check this site: http://www.macroaxis.com/invest/ratio/BHRT--Probability-Of-Bankruptcy
Bioheart is not doing good. Their business went bankrupt and now going downhill.
15 Biotech Top Names For 2015
(OTCQB:AMBS) Amarantus BioScience Holdings, Inc.
(NASDAQ:ASPX) Auspex Pharmaceuticals
(NASDAQ:BCLI) BrainStorm Cell Therapeutics
(NYSEMKT:CUR) Neuralstem
(OTCQX:CYNAF) Cynapsus Therapeutics
(NASDAQ:DEPO) Depomed, Inc.
(NASDAQ:EPRS) Epirus Biopharmacuticals
(NASDAQ:LPCN) Lipocine, Inc.
(NASDAQ:NBIX) Neurocrine Biosciences
(OTCPK:NRIFF) Nuvo Research
(OTCQX:NUOT) Nuo Therapeutics
(OTCQB:NVIV) InVivo Therapeutics
(OTCPK:PRTX) Protalex, Inc.
(OTCQB:TTNP) Titan Pharmaceuticals
(NASDAQ:VCEL) Vericel Corp
Click here for more information!
Event: Biotech Showcase 2015
Date: Wednesday, January 14, 2015
Time: 3:30 p.m. Pacific Time / 6:30 p.m. Eastern Time
Location: Parc 55 Wyndham Union Square, San Francisco, CA
Mr. Commissiong will review results of the full 140-subject LP-002 study assessing the predictive value of LymPro in patients with mild, moderate and severe AD. The results will include the dataset from the initial 72 patients showing that LymPro achieved highly statistically significant results in correctly distinguishing patients with moderate-to-severe AD from healthy controls and from the additional 68 patients in the study's extension to assess LymPro's predictive value in diagnosing early-stage AD.
A live audio webcast of the presentation may be accessed via the News and Events page of the Investor Relations section of the Amarantus corporate web site under the IR Calendar at www.amarantus.com. A webcast replay will be available approximately two hours after the presentation ends and will be archived for 30 days.
- See more at: http://globenewswire.com/news-release/2014/12/29/694086/10113538/en/Amarantus-to-Present-LP-002-Data-for-Alzheimer-s-Blood-Diagnostic-LymPro-Test-R-at-Biotech-Showcase-2015-Conference-on-January-14-2015.html#sthash.vETgZxkL.NCml5G6r.dpuf
Data Storage Corp. ( (DTST) - Pump and Dump Scam
Jason Napodano - 15 Biotech Names For 2015
http://seekingalpha.com/article/2797975-15-biotech-names-for-2015
Amarantus BioScience (AMBS) is aiming to be first to market with an accurate, reliable and commercially- viable diagnostic blood test for Alzheimer's disease.
Data gives them all the information they need to move full steam ahead with this strategy. They can now tailor their initial marketing efforts towards the $150M RUO market, primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials. They have nearly completed assembling the resources needed to launch LymPro to the RUO community. Thereafter, they intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B
I really believe AMBS will be huge!
He also stated that if they do not believe they have achieved sufficient shareholder value creation, they will consider delaying the up list. Need to have patience.
Give me proof that D.T.C. chill order scuttled those plans. Depository Trust Company?
Gerald E. Commissiong - We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above – for the end of 2014 alone – will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.
He is waiting for the right time to Uplist without R/S.
Sounds good!
Hopefully we will get FDA approval for Orphan Indication soon.
Amarantus BioScience Holdings, Inc., a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has applied to the U.S. Food & Drug Administration (FDA) for Orphan Drug Designation for its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) as a treatment for retinal artery occlusion (RAO). RAO is a blockage of the blood supply to the retina which causes severe and sudden loss of vision.
"LymPro is now available to pharmaceutical companies for investigational use in the recruitment of subjects in their Alzheimer's disease clinical studies," commented Colin Bier, Amarantus' corporate advisor and LymPro program lead. "We believe this diagnostic blood test has the potential to be an extremely valuable tool to assist pharma companies in selecting subjects to enroll in their Alzheimer's therapeutic clinical development programs and mitigating the risk of enrolling subjects into clinical trials who do not meet the criteria of Alzheimer's disease. LymPro will have a significant positive impact on the overall outcome of their trials, ultimately benefiting the millions of patients and their families suffering from this horribly debilitating disease."
http://ir.stockpr.com/amarantus/company-news/detail/1834/amarantus-commences-launch-of-proprietary-alzheimers-blood-diagnostic-lympro-testr-to-pharmaceutical-industry-for-use-in-clinical-trials